RepliCel announces development of technology that clones patient hair cells
- Saturday, October 29, 2011, 0:52
- Male Hair Loss, New Scientific Discoveries
- 2,853 views
- Add a comment
RepliCel Life Sciences Inc. (REPCF) has developed RepliCel(TM), a natural hair cell replication technology that the company believes has the potential to become the first minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. RepliCel(TM) is based on autologous cell implantation technology that replicates a patient’s hair cells from his or her own healthy hair follicles. The company’s technology is designed to initiate natural hair regeneration when the hair cells are reintroduced into areas of hair loss. Patents have been issued by the European Union and Australia and are pending in other major international jurisdictions.
In December 2010, RepliCel completed the acquisition of two subsidiaries, TrichoScience Innovations Inc. and 583885 B.C. Ltd., pursuant to share exchange agreements. As a result of these acquisitions, the company’s business became the development of hair cell replication technology.
The company’s cellular replication and implantation technology is designed to grow new hair follicles in patients suffering from androgenetic alopecia as well as other causes of balding or thinning scalp hair. The procedure is also designed to rejuvenate damaged, miniaturized hair follicles in balding scalp skin.
The mechanics of RepliCel’s technology involve the extraction of as few as 10 to 20 hair follicles from a patient. The cells are then replicated in a laboratory through the company’s cellular replication process and injected back into the patient’s scalp in balding areas. It is anticipated that the implanted cells will induce the formation and growth of new hair follicles and will also help rejuvenate damaged hair follicles. RepliCel’s anticipated long-term result is the restoration of a full head of hair that has been seeded by the patient’s own natural hair cells.
RepliCel(TM) is based on autologous cell implantation technology that replicates a patient’s hair cells from his or her own healthy hair follicles.
S&P Factual Stock Report coverage on RepliCel Life Sciences, Inc. will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit www.replicel.com for additional information.
About Standard & Poor’s Factual Stock Reports
This Standard & Poor’s service provides factual research coverage enabling information about RepliCel Life Sciences, Inc. and other securities to reach a wide investor audience of Buy and Sell-side investors, helping them understand a company’s fundamentals and business prospects. Currently profiling over 500 issuers, S&P Factual Stock Reports increase market awareness for issuers in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, Industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks.
Standard & Poor’s Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor’s. Standard & Poor’s Factual Report research has no access to non-public information received by other units of Standard & Poor’s. Standard & Poor’s does not trade on its own account.
Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P’s STARS research) are eligible to obtain this coverage.
About Standard & Poor’s
Standard & Poor’s, a division of The McGraw-Hill Companies MHP +0.36% , is the world’s foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 10,000 employees, including wholly owned affiliates, located in 23 countries, Standard & Poor’s is an essential part of the world’s financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com .
SOURCE: Standard & Poor’s